Related Experiment Video

Updated: Jun 15, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
08:46

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives

Published on: September 16, 2021

Stanozolol treatment for successful prevention of attacks of severe primary cryofibrinogenemia

Sule Unal1, Fehime Kara, Seza Ozen

  • 1Faculty of Medicine, Department of Pediatrics, Division of Pediatric Hematology, Hacettepe University, Ankara, Turkey. suleunal@hacettepe.edu.tr

Pediatric Blood & Cancer
|March 9, 2010
PubMed

Insights

Severe essential cryofibrinogenemia in children is rare and difficult to manage. Stanozolol prophylaxis effectively prevented new skin lesions in an 11-year-old boy unresponsive to other treatments.

Area of Science:

  • Pediatric Hematology
  • Rare Diseases
  • Dermatology

Background:

  • Severe essential cryofibrinogenemia is a rare pediatric condition.
  • Diagnosis and management pose significant challenges for pediatricians.
  • Previous treatments were ineffective for this patient.

Observation:

  • An 11-year-old male presented with a history of digital loss due to cold exposure.
  • The patient was diagnosed with primary cryofibrinogenemia after extensive medical evaluations.
  • Conventional therapies including calcium channel blockers, acetyl salicylic acid, pentoxifylline, dextran, and steroids failed to improve his condition.

Findings:

  • Stanozolol prophylaxis (2 mg/day orally) was initiated for the patient.
  • No new skin lesions developed after starting stanozolol treatment.
  • Existing lesions showed signs of healing during stanozolol therapy.

Implications:

  • Stanozolol may be an effective treatment option for severe pediatric cryofibrinogenemia.
  • This case highlights the potential of stanozolol in managing refractory cryofibrinogenemia.
  • Further research is warranted to confirm stanozolol's efficacy and safety in pediatric patients.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Flail Chest-II01:26

Flail Chest-II

Managing flail chest, a condition characterized by a segment of the chest wall moving independently from the rest of the thoracic cage, requires a comprehensive approach. It includes a thorough assessment of the patient's condition, a diagnostic evaluation to determine the extent of the injury, and the implementation of appropriate medical interventions tailored to the individual's needs.
Assessment:
1. Clinical Evaluation:
History:
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...